Rehabilitation robotics is one of the broadest segments of China’s medical robotics market, spanning clinical devices in hospitals and rehabilitation centers, wearable exoskeletons for outpatient and home use, and specialty systems for pediatric, geriatric, and post-stroke care. NMPA Class II registration predominates in this segment (versus Class III for surgical systems), which has accelerated time-to-market and enabled a larger roster of domestic manufacturers — Yeecon, Fourier Intelligence, Syrebo, Ai-Robotics, BESKAR, Hypershell, and others — alongside established international names.
Key product categories include frame-mounted early-recovery trainers for paraplegia and high-muscle-tone patients (AiDong, BearH), portable lower-limb exoskeletons for gait training (AiKang, MiBot, Keeogo, Hypershell), upper-limb trainers for post-stroke hemiparesis (A2, ArmGuider, BURT, SkyWalker), hand rehabilitation devices including BCI-based and soft-glove systems (Syrebo, ChejIng, BCI Hand), and whole-body platforms for complex neurorehabilitation. Geriatrics and mobility-aid products — power wheelchairs, stair climbers, balance assist devices — are included where they serve rehabilitation indications.
Reimbursement pathways differ meaningfully: clinical-grade rehabilitation systems depend on hospital rehabilitation department procurement and specific provincial reimbursement schedules, while consumer-facing exoskeletons rely on direct sales and emerging outpatient care bundles. For manufacturers entering China, understanding whether a product targets Class II clinical use or consumer wellness affects the entire registration and market access path.
See data methodology for how this listing is maintained.